Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia by Bruining, H.A. (Hajo) et al.
CLINICAL CASE SEMINAR
Fertility and Body Composition after Laparoscopic
Bilateral Adrenalectomy in a 30-Year-Old Female with
Congenital Adrenal Hyperplasia
HILGO BRUINING, ATTE H. BOOTSMA, JAN W. KOPER, JAAP BONJER,
FRANK H. DE JONG, AND STEVEN W. J. LAMBERTS
Departments of Medicine (H.B., A.H.B., J.W.K.) and Surgery (J.B.), University Hospital Rotterdam,
3000 CA Rotterdam; and Department of Medicine (F.H.d.J., S.W.J.L.), Erasmus University Rotterdam,
3000 DR Rotterdam, The Netherlands
ABSTRACT
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is
caused by an inborn defect in the 21-hydroxylase gene (CYP21), lead-
ing to virilization of female patients and causing ambiguous genitals
in the majority of female infants. Adult women may suffer from loss
of libido, irregular or absent cycles, and reduced fertility, despite
intensive medical treatment. These problems have stimulated the
search for alternative treatment modalities. We present an adult
female patient, who was difficult to treat medically and whose clinical
situation markedly improved after laparoscopic bilateral adrenalec-
tomy. The procedure was well tolerated and without side effects.
Postoperatively the elevated serum progesterone and 17-hydroxypro-
gesterone levels, as well as the undetectable LH levels, normalized.
The procedure resulted in marked clinical improvement. Within 12
months after surgery she lost 11 kg in weight. This weight loss con-
sisted mainly of adipose tissue. Acne disappeared, and she had a
regular 4-week menstrual cycle, with progesterone levels that are
compatible with a luteal phase. The introduction of laparoscopic tech-
niques may give an impulse to the application of surgical therapy at
a larger scale in patients with 21-hydroxylase deficiency who are
difficult to treat with adrenal suppression therapy. (J Clin Endocrinol
Metab 86: 482–484, 2001)
CONGENITAL ADRENAL hyperplasia (CAH) due to21-hydroxylase deficiency is caused by an inborn de-
fect in the 21-hydroxylase gene (CYP21; Refs. 1–3). This gene
is normally expressed in the adrenal glands. The genetic
defect causes a deficit in functionally active enzyme, leading
to the inability to synthesize mineralo- and glucocorticoste-
roids. Depending on the type of defect, the level of residual
enzyme can range from a subtle reduction to complete ab-
sence. The decreased synthesis of cortisol results in increased
secretion of ACTH from the pituitary, with subsequent ad-
renal hyperplasia and overproduction of 21-hydroxylase
substrates, which can be further metabolized to androgenic
steroids, leading to virilization of female patients and caus-
ing ambiguous genitals in the majority of female infants.
Growth is initially accelerated, followed by early epiphysial
closure and short stature in both sexes (4–6). Hyperandro-
genism of adrenal origin can induce precocious puberty in
boys. The medical treatment of 21-hydroxylase deficiency
has not been substantially altered since 1950 (7).
Glucocorticoid replacement aims to reduce virilization by
suppression of ACTH stimulation. The reported prescribed
dosages frequently exceed 15 mg cortisol/m2/day, whereas the
normal daily secretion rate is about 7–8 mg/m2 (8, 9). Despite
frequent monitoring and dose adjustments these supraphysi-
ological dosages have been shown to lead to adverse effects like
attenuation of growth, obesity, and decreased bone mineral
density (10–13). In adult life sexual functioning is often im-
paired, both biologically and psychologically (14). Women still
suffer from loss of libido, irregular or absent cycles, and reduced
fertility (6, 15–17). In males suppression of gonadotrophic hor-
mones may induce poor spermatogenesis (4).
These problems have stimulated the search for alternative
treatment modalities (9, 18). It is now possible to carry out
prenatal fetal genotyping in women known to be at risk of
having offspring with 21-hydroxylase deficiency, and affected
female fetuses can be treated in utero to prevent virilization.
Also, bilateral adrenalectomy has been used in patients where
medical suppression of adrenal precursors was difficult to
achieve or was accompanied by serious side effects (19–22).
Patients without any remaining enzyme activity, the so-called
double null mutation carriers, are supposed to be the most
eligible candidates for this approach (9). This invasive treatment
has become more accessible because the patients can be iden-
tified easily by genotyping of the CYP21 gene, and also by the
introduction of laparoscopic adrenalectomy. This procedure is
safe, less mutilating, and well tolerated (23–25). We present a
typical adult female patient with CAH as a result of complete
loss of 21-hydroxylase activity, who was difficult to treat med-
ically and whose clinical situation was markedly improved by
laparoscopic bilateral adrenalectomy.
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The patient
The patient, now a 31-yr-old female, from nonconsanguin-
eous parents, was born with ambiguous genitalia. She went
through a salt-losing crisis shortly after birth and was diag-
nosed as having classical CAH on clinical grounds. At 2 yr
of age a nephropyelotomy and a meatotomy of the urethra
were performed to relieve her from recurrent urinary tract
problems. When she was 4 yr old a clitoral reduction and
correction of the labia were performed, followed by an in-
troitusplasty and vaginoplasty at age 13 and 16, respectively.
She visited the hospital three to four times each year, and on
these occasions circulating hormone levels were checked.
The results were used to adjust the glucocorticoid dose to
keep androstenedione and 17-hydroxyprogesterone levels
within in the normal range using as little medication as
possible. Despite this frequent monitoring and frequent dose
adjustments, she experienced many problems that can ac-
company the treatment of these patients: she did not feel
feminine, had a masculine build, was obese, had irregular
menses with long amenorrhoic periods, and a seborrhoic
skin with acne. Her weight was 79 kg, and her height was 168
cm, whereas her mother and father measured 174 and 180
cm, respectively. She was normotensive (110/70 mm Hg).
Using allele-specific PCR (26) it was determined that the
patient was homozygous for a splice-site mutation in intron
2, which by itself would have resulted in a very low residual
activity of 21-hydroxylase activity (27). In addition, however,
the patient was heterozygous for the five most C-terminal
mutations in the protein: V281 L, Ins T, Q318 ter, R356 W, and
P453 S. At the age of 29 she used dexamethasone at a dose
varying between 0.5 and 1 mg per day in two divided doses
taken at 0900 and 2100 h and 0.0625 mg/day fludrocortisone.
With those treatment regimens serum progesterone and 17-
hydroxyprogesterone concentrations remained well above
the reference levels in our laboratory, whereas serum ACTH
levels were normal. A representative hormonal profile is
shown in Table 1. Furthermore, the LH was suppressed,
which might contribute to the disturbance of her menstrual
cycle (Table 1). A computed tomography scan showed bi-
lateral hyperplasia of both the adrenals.
Laparoscopic biadrenalectomy was offered as alternative
treatment, with the objective to restore the menstrual cycle,
reduce masculinization, and make medical (supplementa-
tion) therapy easier and less intensive.
Adrenalectomy was performed using a standard laparo-
scopic procedure (22–24). The operation and postoperative
recovery were uncomplicated, and discharge from hospital
followed after 3 days. Replacement therapy was started with
10 mg hydrocortisone three times daily and 0.0625 mg
fludrocortisone once daily. Hydrocortisone replacement was
later tapered to 20 mg daily without adverse effects. How-
ever, early morning serum ACTH levels turned out to be
increased. Therefore, hydrocortisone replacement therapy
was increased to 25 mg/day, after which ACTH levels nor-
malized (data not shown). Postoperative laboratory data (Ta-
ble 1) revealed that the serum progesterone and 17-
hydroxyprogesterone levels had normalized and that LH
levels became measurable again. The procedure resulted in
marked clinical improvement. Within 12 months after sur-
gery she had lost 11 kg in weight, her acne had disappeared,
and she had a regular 4-week menstrual cycle, with proges-
terone levels that are compatible with a luteal phase. This
strongly suggests that she ovulated during her menstrual
cycles. Subjective improvement was reported in terms of
increased feeling of well being and femininity. Her physical
activity and capacity were unaltered, subjectively. Body
composition and bone mineral density were assessed by
dual-energy x-ray absorptiometry using a Lunar DPX-L den-
sitometer (Lunar Corp., Madison, WI) before and after sur-
gery (Table 2). The results show that loss of fat completely
accounted for her weight loss. Lean body mass and bone
mineral density did not change.
Discussion
Here, we report the excellent clinical effect of bilateral
laparoscopic adrenalectomy in an adult female with classical
CAH. The patient, like many of her fellow patients, had
experienced virilizing and masculinizing effects from birth to
adulthood, despite intensive follow-up and variable doses of
medical treatment. Recently, laparoscopic adrenalectomy
TABLE 1. Laboratory results





FSH (IU/L) 1–7 5.2 8.0 8.9 1.7
LH (IU/L) 1–8 ,0.1 2.5 2.3 0.67
Progesteroneb (nmol/L) F: 0.5–3 109 0.6 0.9 18
Oestradiol (pmol/L) F: 50–400 52 117 85 280
L: 200–800
17-OH-progesterone (nmol/L) F: 0.5–2 28.6 0.3 0.1 0.1
L: 1.5–10
Serum ACTH (ng/L) 15–65 11–26 950
Medication
mg/day Dexamethasone 0.75
mg/day Hydrocortisone 30 30 20
mg/day Fludrocortisone 0.0625 0.0625 0.0625 0.0625
F, Follicular phase of the menstrual cycle; L, luteal phase of the menstrual cycle.
a One hormonal profile is presented preoperatively, which is representative of many measurements over a period of 6 yr under variable doses
of dexamethasone (0.5–1 mg/day).
b Serum LH, FSH, progesterone, and oestradiol concentrations measured preoperatively, as well as 3 and 6 months after operation, were
not related to the menstrual cycle, which was abnormal. However, menstrual cycles had normalized 12 months after bilateral adrenalectomy,
and the serum gonadotropin and steroid hormone concentrations at that time were drawn on day 24 of the menstrual cycle.
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was introduced as a new modality for surgical treatment. The
availability of ample local expertise with this procedure for
different indications (24) helped us with the decision to offer
our patient bilateral adrenalectomy as the alternative for the
medical treatment of the sequelae of her CAH. This proce-
dure would completely deprive her of all adrenal steroid
hormone precursors and their (masculinizing) effects. Earlier
studies have shown that the hyperplastic adrenal is not help-
ful in times of stress. It has been demonstrated that adrenal
steroid precursors promote salt wasting under stress condi-
tions in both patients and healthy volunteers (28). On the
other hand, clinically beneficial effects of steroid precursors
have recently been reported for dehydroepiandrosterone
(DHEA): suppletion of DHEA restored libido in DHEA-
deficient women (29, 30). These findings necessitate careful
follow-up of adrenalectomized women to determine whether
suppletion to physiological dosages of steroid precursors is
indicated to further improve their quality of life. Follow-up is
also required because failure of surgical therapy with recur-
rence of virilization several years later has been reported (20).
Virilization in those patients was driven by either ovarian ste-
roidogenesis or hormone production in ectopic adrenal tissue
(20, 21). To date, the frequency and clinical importance of these
failures in adrenalectomized patients have not been deter-
mined. Procedure-related complications are impressively low
in experienced hands (23, 24).
In our patient, a good short-term result was obtained. All
preoperative goals were met, without any complications ei-
ther related to the procedure or to the hormonal replacement
therapy afterward. This is in line with the data reported on
patients with classic adrenal hyperplasia who were treated
by biadrenalectomy by different techniques or earlier in their
lives (9, 18–21). The introduction of laparoscopic techniques
may give an impulse to the application of surgical therapy
at a larger scale in cases that are difficult to treat with adrenal
suppression therapy.
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Fat mass (kg) 31.8 (41%) 24.1 (35%) 21.0 (31%)




Z-score (SD) 0.4 0.6 0.7
Total body mass (kg) 79 71 68
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